Xenetic to merge with Santersus, creating SNTS with NETs pipeline
Xenetic Biosciences announced a definitive share-exchange to acquire Santersus AG, forming Santersus Bio, Inc. and listing on Nasdaq as SNTS. The combined company will pursue NET-targeting therapies via NucleoCapture and DNase, with four pivotal trials including sepsis and SLE; XBIO's stock fell about 41% on the news amid dilution and integration concerns.
View signal analysis